Le Lézard
Classified in: Health, Science and technology
Subject: FDA

VeraSci Receives FDA Grant to Support Qualification of the Virtual Reality Functional Capacity Assessment Tool (VRFCAT)


DURHAM, N.C., Sept. 5, 2019 /PRNewswire/ -- VeraSci, a leading provider of innovative scientific and biotechnology services, announced today that they have received an FDA grant to conduct further research on the VRFCAT, their proprietary functional capacity assessment. The VRFCAT has recently been accepted into the FDA's COA Qualification Program as a measure of functional capacity for schizophrenia treatment trials. This project will use qualitative research methods to establish the clinical meaningfulness of this measure to patients, family members, and peer support specialists. Qualitative evidence supporting the clinical meaningfulness of the VRFCAT from patient and caregiver perspectives will help advance the VRFCAT through the FDA qualification process and is a key component of interest for payers and health care providers.

VeraSci logo (PRNewsfoto/VeraSci)

The VRFCAT is an eCOA task that simulates key instrumental activities of daily living (iADLS) in a realistic and interactive virtual environment. With demonstrated sensitivity to accepted measures of cognitive and functional deficits in multiple CNS disorders, the VRFCAT was developed in VeraSci's Innovation Lab to improve clinical trials by detecting functionally meaningful improvements in patients' everyday lives. The VRFCAT has numerous advantages over conventional assessments, and meets the highest psychometric standards, with strong support from industry sponsors, NIH and FDA as a functional co-primary outcome measure.

If you are interested in learning more about or demoing the VRFCAT, visit https://verasci.com/vrfcat/.

About VeraSci

Founded in 2004, VeraSci has a worldwide presence in clinical trial development, clinical and cognitive assessment and language services. VeraSci brings deep expertise, strategic innovation and unwavering commitment to every project, allowing each client to deliver data supporting innovative therapies.

For more information, press only:
PR Contact Name: Ashley Davis, Marketing Communications Manager
Phone number: 919-401-4642
Email: [email protected]
Website: www.VeraSci.com

SOURCE VeraSci


These press releases may also interest you

at 22:18
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...

at 21:51
On March 19, DMEGC Solar received the Acknowledgement of Manufacturer's Laboratory Competence issued by TÜV Rheinland, a global certification agency, proving its excellence in PV module R&D and quality control. The acknowledgement is TÜV Rheinland's...

at 21:45
Shop TJC Ltd. (TJC) is thrilled to announce the successful completion of its third collaboration with the iconic BBC...

at 21:32
Arctech has recently signed a contract for the 500MW Manah I power plant project in Oman, following its successful bid for the 588MW Manah II PV project in Oman earlier in 2023. This consecutive project win showcases Arctech's customized solutions...

at 21:15
Techtouch, Inc. (Headquarter: Tokyo, Japan, President/CEO: Naka Imuta) announced today that it ranked 8th in the 21st Technology Fast 50 Japan, with three-year revenue growth of 468.6%. Technology Fast 50 Japan, held annually by Deloitte Tohmatsu...

at 21:00
OKX Ventures, the investment arm of leading crypto exchange and Web3 technology company OKX, today published a report titled 'Unlocking the Infinite Potential of Crypto and AI.' The report explores the convergence of AI and crypto, a major trend in...



News published on and distributed by: